Baxter International Inc

BAX

Equity

ISIN null / Valor 911702

New York Stock Exchange, Inc (2025-10-21)

USD 22.75-1.64%

Baxter International Inc
UMushroom community rating:

3.00 1 votes No rating yet

NegativeNeutralPositive

About company

Baxter International Inc is a global healthcare company that focuses on hospital, nutrition, renal, and surgical care. The company provides a range of products and services, including hemostatic agents, generic injectables, parenteral nutrition systems, and dialysis therapies. Baxter BioPharma Solutions, a contract manufacturing organization, has entered into agreements with leading companies to provide manufacturing services for COVID-19 vaccines and diagnostic tests. The company's recent acquisition of Hillrom has expanded its opportunities for innovation and access to care worldwide. Baxter is committed to transforming healthcare and advancing patient care from the hospital to the home, with a focus on improving outcomes for patients with chronic conditions such as end-stage renal disease.

Summarized from source with an LLMView SourceSector: Healthcare

Sales Growth and Earnings

Second-quarter worldwide sales from continuing operations totaled approximately $2.81 billion, marking a 4% increase on a reported basis and a 1% rise on an operational basis. Adjusted diluted earnings per share from continuing operations were $0.59, reflecting a 28% increase over the prior year, while U.S. GAAP diluted EPS stood at $0.24.

Leadership Appointment

Baxter announced the appointment of Andrew Hider as the new President and Chief Executive Officer. Hider's extensive experience in driving operational excellence and innovation is expected to accelerate Baxter’s growth and enhance shareholder value.

Segment Performance

The Medical Products & Therapies segment reported sales of $1.32 billion, remaining flat on a reported basis and increasing by 1% operationally. Healthcare Systems & Technologies achieved $767 million in sales, a 3% reported and 2% operational increase. Pharmaceuticals sales reached $612 million, up 2% on a reported basis and 1% operationally.

Strategic Initiatives

Baxter has advanced key strategic priorities, including restoring inventory levels affected by Hurricane Helene and partnering with Vizient to enhance the reliability of IV fluid supplies. Additionally, the company published its 2024 Corporate Responsibility Report, underscoring its commitment to sustainability and responsible business practices.

Financial Outlook

For the full year 2025, Baxter anticipates sales growth from continuing operations of 6% to 7% on a reported basis and 3% to 4% operationally. The company projects adjusted earnings from continuing operations of $2.42 to $2.52 per diluted share, aligning with its strategic focus on growth and operational efficiency.

Summarized from source with an LLMView Source

Key figures

-37.8%1Y

-59.7%3Y

-72.2%5Y

Performance

42.2%1Y

35.1%3Y

31.1%5Y

Volatility